European Commission approves Pfizer's VELSIPITY® for patients with moderately to severely Active ulcerative colitis
Pfizer Inc. (NYSE: PFE) announced that the European Commission (EC) has granted marketing authorization for VELSIPITY® (etrasimod) in the European Union to treat patients 16...